Rezaiee Razie, Ghazizadeh Hamideh, Darroudi Susan, Zirak Roshanak Ghaffarian, Rohban Mohadese, Eidi Marziyeh, Jam Irandokht Nikbakht, Mahmoudi Ali Asghar, Hadizadeh Farzin, Aghasizadeh Malihe, Mohtashamian Abbas, Ghayour-Mobarhan Majid
Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Sci Rep. 2025 Aug 15;15(1):29975. doi: 10.1038/s41598-025-15953-2.
The aim of this study was to investigate the effect of Crocin on the inflammatory cytokines profile in patients with Metabolic syndrome (Mets). Twenty-eight patients with Mets (15 cases and 13 controls) were randomly selected by the International Diabetes Federation (IDF) definite criteria in a double-blind randomized clinical trial. Participants were divided into two treatment groups, a group received 15 mg of Crocin (two tablets per day), and the other one received a placebo for eight weeks. Inflammatory and growth factors were measured using a sandwich chemiluminescence assay, before and after treatment. Our results indicated that inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment. Moreover, no significant difference was detected among the other biochemical factors (lipid profile and FBG) between two groups. The results showed the exclusive impact of Crocin on the reduction of serum inflammatory cytokines. Crocin has the potential to be further investigated as a useful therapeutic factor in inflammatory diseases.Clinical trial registration number: IRCT2013080514279N1, Registration date: 01/02/2015.
本研究旨在探讨藏红花素对代谢综合征（Mets）患者炎症细胞因子谱的影响。在一项双盲随机临床试验中，根据国际糖尿病联盟（IDF）的明确标准随机选取了28例代谢综合征患者（15例病例和13例对照）。参与者被分为两个治疗组，一组接受15毫克藏红花素（每天两片），另一组接受安慰剂，为期8周。在治疗前后，使用夹心化学发光分析法测量炎症和生长因子。我们的结果表明，藏红花素治疗后，代谢综合征患者的炎症因子，包括白细胞介素-2（IL-2）、白细胞介素-10（IL-10）、血管内皮生长因子（VEGF）和干扰素γ（INFγ）显著降低（P < 0.05）。此外，两组之间的其他生化因子（血脂谱和空腹血糖）未检测到显著差异。结果显示藏红花素对降低血清炎症细胞因子具有独特作用。藏红花素有可能作为炎症性疾病的一种有用治疗因子进一步研究。临床试验注册号：IRCT2013080514279N1，注册日期：2015年2月1日。
